HUM-MOLGEN events: Cambridge Healthtech Institute's Recombinant Antibodies

HUM-MOLGEN -> Events -> Meetings and Conferences

Cambridge Healthtech Institute's Recombinant Antibodies

January 28, 2003

Cambridge Healthtech Institute, Hyatt Regency Cambridge, 575 Memorial Drive, Cambridge, MA 02139
May 12-13, 2003

Technologies for Antibody Selection
An Array-Based System for High-Throughput Binding Kinetics Analysis by Surface Plasmon Resonance: Application to Hybridoma Screening
Covalent Antibody Display by a P2 Phage Replication Protein
Generation of Antibody Therapeutics by Phage and Ribosome Display
Human Fab Antibody Isolation and Rapid Affinity Maturation Using an Integrated Phage and Yeast Display Platform
Naïve Yeast Display Libraries
Rapid Cell Line Enrichment for High Secretors and Rare Cells

Antibody Engineering and Optimization
Predicting and Overcoming Immunogenicity via T Cell Epitopes
Rational Engineering of Monoclonal Antibodies
A General Solution for Stable Cytoplasmic Intrabodies
Recombinant Polyclonal Antibody Libraries to Human Colorectal Cancer
Human Recombinant Antibodies with MHC-Restricted T Cell Receptor-like Specificity
The Biophysical Properties of Fully Human Domain Antibodies

Beyond Antibodies
Fluorobodies: Binding Ligands with Intrinsic Fluorescence
Structural Design of High-Affinity Antibody-like Domains
TRINECTIN™ Antibody Mimics

Antibodies in Proteomics and Target Discovery
Use of Reverse-Phase Protein Arrays for Signal Pathway Profiling
Rolling Circle Amplification in Proteomic Applications with Ultrasensitive Multiplex Immunoassays
"Immunization" with Subcellular Compartments and Use of Scfvs as Protein Conformation Sensors in Living Cells

Therapeutic Applications of Antibodies and Antibody Fragments
Radioimmunotherapy (RIT): Current Status and Future Prospects
Recombinant Immunotoxins for the Treatment of Hematologic Malignancies
Immunoliposomes Targeted Using scFvs
Development of Potent and Highly Effective Monoclonal Antibody-Auristatin Conjugates for Cancer Therapy
HuCAL® Antibodies: Designed as Therapeutics

Organized by:

Cambridge Healthtech Institute

Invited Speakers:

Dr. Yevgenya Akselband, One Cell Systems, Inc.
Dr. Jaime Arenas, Applied Biosystems
Dr. Michael Bardroff, MorphoSys AG (Germany)
Dr. Itai Benhar, Tel-Aviv University (Israel)
Dr. Laird Bloom, Phylos, Inc.
Dr. Andrew Bradbury, Los Alamos National Laboratories
Dr. Frank Carr, Biovation (UK)
Dr. Chaitanya Divgi, Weill Medical College of Cornell University and Memorial Sloan-Kettering Cancer Center
Dr. Stephen K. Doberstein, Xencor
Dr. Dominik Escher, CEO ESBATech AG (Switzerland)
Dr. Michael Feldhaus, Pacific Northwest National Laboratories
Dr. Peter J. Hudson, CSIRO Health Science and Nutrition (Australia)
Dr. Simon E. Hufton, Dyax S.A. (Belgium)
Dr. Laurent Jespers, Domantis (UK)
Dr. Robert J. Kreitman, National Cancer Institute, National Institutes of Health
Dr. James D. Marks, University of California, San Francisco
Dr. Michael C. Mullenix, Molecular Staging Inc.
Dr. John W. Park, University of California, San Francisco
Dr. Franck Perez, Institut Curie (France)
Dr. Emanuel F. Petricoin III, U.S. Food and Drug Administration
Dr. Herald Reiersen, Affitech AS (Norway)
Dr. Yoram Reiter, Technion-Israel Institute of Technology
Dr. Peter Senter, Seattle Genetics
Dr. Jackie Sharon, Boston University School of Medicine
Dr. Celia P. Shorrock, Cambridge Antibody Technology (UK)

Preconference Tutorial
Comparison of Display Technologies for Making
Therapeutic Antibodies ay 13, 5:30 pm - 8:30 pm

Deadline for Abstracts:

April 4, 2003

Registration:

Available Online Call:617-630-1300/fax: 617-630-1325 e-mail: chi@healthtech.com

E-mail:

eeskedal@healthtech.com

Posted by:

elaine eskedal

Host:

wks152.healthtech.com